Sir,

Nephrogenic systemic fibrosis (NSF) is a rare and debilitating disorder, which affects patients with kidney failure. An association with gadolinium-based contrast agents for magnetic resonance imaging (MRI) was found [1]. However, not all NSF patients had a prior gadolinium exposure [2]. Recently, an association of NSF and the use of erythropoietin was proposed [3]. Our aim was, thus, to investigate the use of gadolinium-based contrast agents and erythropoietin in haemodialysis patients with and without NSF.

Four patients in our dialysis unit developed NSF (between 2002 and 2006). We retrospectively compared those to all other patients requiring chronic haemodialysis (n = 61; data collection in August 2007). Besides demographic characteristics, we investigated haemoglobin levels, iron and erythropoietin supplementation, parameters of inflammation, Kt/V and exposure to gadolinium.

Table 1 gives the basic characteristics of patients and controls. There were no differences with regard to age, sex, number of previous kidney transplantsations, cumulative time on haemodialysis or primary renal disease. The same was true for Kt/V. The haemoglobin levels were comparable, but NSF patients received higher doses of erythropoietin (331.1 ± 215.1 versus 133.3 ± 99.5 U/week/kg body weight; \( P < 0.05 \)). In the NSF group, 4/4 of the patients received erythropoietin and in the control group 53/61 (\( P > 0.05 \)).

In the NSF group, on average, more contrast enhanced MRIs had been performed (3.0 ± 1.2 per patient (range 2–4) versus 1.8 ± 2.0 per patient (range 0–10); the mean dose contrast agent 12.6 ± 5.4 versus 11.6 ± 4.6 mmol/MRI). In the control group, the following contrast agents were used: gadopentetate dimeglumine 94 times, gadodiamide 9 times, gadobutrol 4 times and gadobenate dimeglumine once. In the NSF group, gadopentetate dimeglumine and gadodiamide were used six times each. The cumulative dose of contrast agent was higher in the NSF group (0.57 ± 0.14 versus 0.29 ± 0.37 mmol/kg body weight; \( P < 0.05 \)). In the NSF group, the time from the last administration of a contrast agent to the first symptoms was 2 weeks till 5 months. Comparing those patients with a minimum of two MRIs (as this is the minimum number in the NSF group) patients in the NSF group, again, received higher doses of erythropoietin (331.1 ± 215.1 versus 128.1 ± 215.1 U/week/kg body weight; \( P < 0.05 \)).

There is growing evidence for a pathogenic role of gadolinium ions as causing agents in the development of NSF [1]. However, not all patients with NSF have been exposed to gadolinium-containing contrast agents [2,5,6]. There seems to be a reasonable likelihood of additional (co-)triggers, which may—alone or in combinations—play a role in the pathogenesis of NSF. In some studies, an association between erythropoietin and NSF [3,7,8] could be found, while not in others [6,9]. One of the cardinal features of NSF is the presence of CD34+ fibrocytes [10]. These cells resemble bone marrow-derived progenitors. One hypothesis says that erythropoietin could drive the development of NSF by increasing the number of circulating haematopoietic stem cells and endothelial progenitor cells, thereby increasing the pool of CD34+ cells. These cells finally may enter the tissue and enhance the fibrotic process. Alternatively, the higher dosage might also reflect erythropoietin resistance in the presence of chronic inflammation, making higher dosages necessary to achieve equal levels of haemoglobin [3,4,11].

The findings of our study have to be interpreted cautiously. The number of NSF patients is small and whether the association with erythropoietin is causative or reflects erythropoietin resistance cannot be answered. However, even if gadolinium seems to be the major culprit in the development of NSF, there is no final proof and a number of questions remain open. The search for (co-)triggers in the development of NSF is strongly warranted. This is especially true in light of limited treatment options of this disabling disease.

Conflict of interest statement. None declared.

1Section of Rheumatology and Nephrology, 2nd Department of Medicine and 2Department of Radiology, General Hospital Linz, Krankenhausstr. 9 A-4020 Linz, Austria

E-mail: herwig.pieringer@akh.linz.at

1. Broome DR, Girgis MS, Baron PW et al. Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. AJR Am J Roentgenol 2007; 188: 586–592
2. Wahba IM, Simpson EL, White K. Gadolinium is not the only trigger for nephrogenic systemic fibrosis: insights from two cases and review of the recent literature. Am J Transplant 2007; 7: 2425–2432
3. Swanianathan S, Ahmed I, McCarthy JT et al. Nephrogenic fibrosing dermopathy and high-dose erythropoietin therapy. Ann Intern Med 2006; 145: 234–235
4. Yerram P, Saab G, Karuparthi PR et al. Nephrogenic systemic fibrosis: a mysterious disease in patients with renal failure—role of
Table 1. Basic characteristics and laboratory parameters

|                          | Controls (n = 61) | NSF patients (n = 4) | P-value |
|--------------------------|------------------|----------------------|---------|
| Age (years)              | 58.2 ± 15.6      | 50.6 ± 18.5          | 0.36    |
| Sex (m/f)                | 49/12            | 3/1                  | >0.05   |
| Patients with prior KTX  | (n; range)       | 17 (1–4)             |         |
| Time of ESRD             | 4.5 ± 6.2        | 2.6 ± 3.3            | 0.56    |
| Kt/V                     | 1.1 ± 0.2        | 1.0 ± 0.3            | 0.36    |
| Systolic blood pressure  | 138.6 ± 24.7     | 153.8 ± 21.7         | 0.23    |
| Diastolic blood pressure | 73.6 ± 15.0      | 81.3 ± 8.5           | 0.32    |
| Antihypertensive drugs   | 2.0 ± 1.7        | 1.3 ± 1.3            | 0.41    |
| Primary renal disease    |                  |                      | >0.05   |
| Diabetic nephropathy     | 20 (32.8%)       | 2 (50%)              |         |
| Vascular nephropathy     | 7 (11.5%)        | 1 (25%)              |         |
| Glomerulonephritis       | 19 (31.1%)       | –                    |         |
| Interstitial nephritis   | 2 (3.3%)         | –                    |         |
| Reflux nephropathy       | 3 (4.9%)         | –                    |         |
| Tumour                   | 3 (4.9%)         | 1 (25%)              |         |
| Others                   | 2 (3.3%)         | –                    |         |
| Unknown                  | 5 (8.2%)         | –                    |         |
| Haemoglobin (mg/dl)      | 12.0 ± 1.3       | 11.0 ± 1.0           | 0.15    |
| Serum iron (µg/dl)       | 66.3 ± 28.9      | 35.5 ± 12.5          | 0.04    |
| Transferrin (mg/dl)      | 184.7 ± 38.3     | 146.8 ± 20.0         | 0.06    |
| Transferrin saturation (%)| 26.4 ± 13.3    | 17.5 ± 6.9           | 0.19    |
| Ferritin (µg/ml)         | 459.6 ± 349.4    | 536.0 ± 254.2        | 0.67    |
| CRP                      | 2.0 ± 3.0        | 2.7 ± 1.9            | 0.68    |

CRP: C-reactive protein; ESRD: end-stage renal disease; KTX: kidney transplantation.

Cystatin C as a surrogate for glomerular filtration rate in the presence of proteinuria

Sir,

All methods for assessing glomerular filtration rate (GFR) have shortcomings. Serum creatinine has a reciprocal relationship to GFR that is related to age, race, sex and muscle mass and is affected by tubular secretion. Creatinine clearance requires a timed urine collection, and radio isotope and inulin clearance methods are expensive. Estimated GFR may only be valid in the steady state of chronic kidney disease (CKD) [1].

There has been much [2] interest in cystatin C, a serine protease inhibitor produced by all nucleated cells, freely filtered at the glomerulus and, although reabsorbed, apparently fully metabolized in tubular cells [3]. Serum cystatin C may be more sensitive to changes in GFR than serum creatinine [4,5].

Renal disease is often accompanied by proteinuria, the severity of which correlates with progression [6], possibly because protein in the tubular fluid injures tubular cells via mechanisms involving reactive oxygen species [7]. We hypothesized that proximal tubular injury by proteinuria might affect cellular handling of cystatin C, leading to an altered relationship to GFR.

We measured serum cystatin C in 65 nephrology-clinic patients, with and without proteinuria, using a latex-enhanced immunonephelometric assay based on rabbit polyclonal antibodies (Dade Behring, UK) with a ProSpec analyser (Dade Behring, UK). Urinary creatinine and protein were measured using standard chemistries on Roche Modular systems (Roche/Hitachi, Roche Diagnostics, Gmbh, Germany). GFR was estimated using the modification of diet in renal disease (MDRD) formula [8]. Patients were being treated for stable CKD secondary to primary glomerulonephritis (28%), diabetes (15%), vasculitis or lupus (8%), chronic pyelonephritis (6%), hypertensive nephrosclerosis (3%), miscellaneous conditions (16%) or unknown cause (24%). They were classified as proteinuric patients if they had proteinuria of more than 300 mg/24 h.

Advance Access publication 9 April 2008

Cystatin C as a surrogate for glomerular filtration rate in the presence of proteinuria

Sir,

All methods for assessing glomerular filtration rate (GFR) have shortcomings. Serum creatinine has a reciprocal relationship to GFR that is related to age, race, sex and muscle mass and is affected by tubular secretion. Creatinine clearance requires a timed urine collection, and radio isotope and inulin clearance methods are expensive. Estimated GFR may only be valid in the steady state of chronic kidney disease (CKD) [1].

There has been much [2] interest in cystatin C, a serine protease inhibitor produced by all nucleated cells, freely filtered at the glomerulus and, although reabsorbed, apparently fully metabolized in tubular cells [3]. Serum cystatin C may be more sensitive to changes in GFR than serum creatinine [4,5].

Renal disease is often accompanied by proteinuria, the severity of which correlates with progression [6], possibly because protein in the tubular fluid injures tubular cells via mechanisms involving reactive oxygen species [7]. We hypothesized that proximal tubular injury by proteinuria might affect cellular handling of cystatin C, leading to an altered relationship to GFR.

We measured serum cystatin C in 65 nephrology-clinic patients, with and without proteinuria, using a latex-enhanced immunonephelometric assay based on rabbit polyclonal antibodies (Dade Behring, UK) with a ProSpec analyser (Dade Behring, UK). Urinary creatinine and protein were measured using standard chemistries on Roche Modular systems (Roche/Hitachi, Roche Diagnostics, Gmbh, Germany). GFR was estimated using the modification of diet in renal disease (MDRD) formula [8]. Patients were being treated for stable CKD secondary to primary glomerulonephritis (28%), diabetes (15%), vasculitis or lupus (8%), chronic pyelonephritis (6%), hypertensive nephrosclerosis (3%), miscellaneous conditions (16%) or unknown cause (24%). They were classified as proteinuric patients if they had proteinuria of more than 300 mg/24 h.

doi: 10.1093/ndtplus/sfn030

1. Leung N, Swaminathan S, Ahmed I et al. Erythropoietin, gadolinium, and nephrogenic fibrosing dermopathy—author reply. Ann Intern Med 2007; 146: 230
2. Goveia M, Chan BP, Patel PR. Evaluating the role of recombinant erythropoietin in nephrogenic systemic fibrosis. Nephrol Dial Transplant 2007; 22: 3174–3178
3. Othersen JB, Maize JC, Woolson RF et al. Nephrogenic systemic fibrosis after exposure to gadolinium in patients with renal failure. Nephrol Dial Transplant 2007; 22: 3179–3185
4. Marckmann P, Skov L, Rossen K et al. Case-control study of gadodiamide-related nephrogenic systemic fibrosis. Nephrol Dial Transplant 2007; 22: 3174–3178
5. Othersen JB, Maize JC, Woolson RF et al. Nephrogenic systemic fibrosis after exposure to gadolinium in patients with renal failure. Nephrol Dial Transplant 2007; 22: 3179–3185
6. Centers for Disease Control and Prevention (CDC). Nephrogenic fibrosing dermopathy associated with exposure to gadolinium-containing contrast agents—St. Louis, Missouri, 2002–2006. MMWR Morb Mortal Wkly Rep 2007; 56: 137–141
7. Goveia M, Chan BP, Patel PR. Evaluating the role of recombinant erythropoietin in nephrogenic systemic fibrosis. J Am Acad Dermatol 2007; 57: 725–727
8. Perazella MA. Nephrogenic systemic fibrosis, kidney disease, and gadolinium-based contrast media in causation and the beneficial effect of intravenous sodium thiosulfate. Clin J Am Soc Nephrol 2007; 2: 258–263
9. Morris SL, Swaminathan S, Ahmed I et al. Erythropoietin, gadolinium, and nephrogenic fibrosing dermopathy—a prospective controlled study. Nephrol Dial Transplant 2007; 22: 3174–3178
10. Othersen JB, Maize JC, Woolson RF et al. Nephrogenic systemic fibrosis after exposure to gadolinium in patients with renal failure. Nephrol Dial Transplant 2007; 22: 3179–3185
11. Perazella MA. Nephrogenic systemic fibrosis, kidney disease, and gadolinium: is there a link? Clin J Am Soc Nephrol 2007; 2: 200–202

CRP: C-reactive protein; ESRD: end-stage renal disease; KTX: kidney transplantation.